Gelita and R.P. Scherer End 60 Year Joint Venture
GELITA AG has come to an agreement with the US company Catalent Pharma Solutions Inc., Somerset, NJ, the majority shareholder of R. P. Scherer GmbH & Co. KG located in Eberbach, Germany, for acquisition of its 49% shareholding in the company. The completion of the transaction is subject to customary closing conditions including approval from regulatory authorities.
Jan 30 2012 --- Gelita AG has come to an agreement with the US company Catalent Pharma Solutions Inc., Somerset, NJ, the majority shareholder of R. P. Scherer GmbH & Co. KG located in Eberbach, Germany, for acquisition of its 49% shareholding in the company.
The completion of the transaction is subject to customary closing conditions including approval from regulatory authorities.
With over 9,000 employees at more than 20 sites, Catalent is a major player in the pharmaceutical industry. For over 10 years, Gelita AG has treated the shareholding in R.P. Scherer as a purely financial investment and not as part of the core business. The joint venture between Gelita and R.P. Scherer, which was one of the first German-American joint ventures following the Second World War, now comes to an end after more than 60 years. Gelita will continue to provide the R.P. Scherer plant, located on the premises of Gelita AG, with gelatin, energy, steam, fresh water etc.
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.